Abstract
Muscarinic and nicotinic are the names given to the two major classes of acetylcholine receptors. These receptors play major roles in the function of the body. In brain, evidence suggests a role for muscarinic receptors in memory function. Therefore, these receptors have been a focus of interest for the therapeutics of Alzheimer’s disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
H.H. Dale, The action of certain esters and ethers of choline, and their relation to muscarine, J. Pharmacol. Exp. Ther. 6: 147 (1914).
M. Raiteri, R. Leardi, and M. Marchi, Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain, J. Pharmacol. Exp. Ther. 228: 209 (1984).
A. Akaike, M. Sasa, and S. Takaori, Muscarinic inhibition as a dominant role in cholinergic regulation of transmission in the caudate nucleus, J. Pharmacol. Exp. Ther. 246: 1129 (1988).
E.S. Vizi, O. Kobayashi, A. Torocsik, M. Kinjo, H. Nagashima, N. Manabe, P.L. Goldiner, P.E. Potter, and F.F. Foldes, Heterogeneity of presynaptic muscarinic receptors involved in modulation of transmitter release. Neuroscience 31: 259 (1989).
M. Raiteri, M. Marchi, P. Paudice, and A. Pittaluga, Muscarinic receptors mediating inhibition of Îł-aminobutyric acid release in rat corpus striatum and their pharmacological characterization, J. Pharmacol. Exp. Ther. 254: 496 (1990).
J.K. Wamsley, M.A. Zarbin, and M.J. Kuhar, Distribution of muscarinic cholinergic high and low affinity agonist binding sites:a light microscopic autoradiographic study, Brain Res. Bull. 12: 233 (1984).
R. Cortes, A. Probst, H.J. Tobler, and J.M. Palacios, Muscarinic cholinergic receptor subtypes in the human brain. II. quantitative autoradiographic studies, Brain Res. 362: 239 (1986).
T. Kubo, K. Fukuda, A. Mikami, A. Maeda, H. Takahashi, M. Mishina, T. Haga, K. Haga, A. Ichiyama, K. Kangawa, M. Kojima, H. Matsuo, T. Hirose, S. Numa, Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor, Nature 323: 411 (1986).
T. Kubo, A. Maeda, K. Sugimoto, I. Akiba, A. Mikami, H. Takahashi, T. Haga, K. Haga, A. Ichiyama, K. Kangawa, H. Matsuo, T. Hirose, and S. Numa, Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence, FEBS Letters 209: 367 (1986).
E.G. Peralta, J.W. Sinslow, G.L. Peterson, D.H. Smith, A. Ashkenazi, J. Ramachandran, M.I. Schimerlik, and D.J. Capon, Primary structure and biochemical properties of an M2 muscarinic receptor, Science 236: 600 (1987).
T.I. Bonner, N.J. Buckley, A.C. Young, and M.R. Brann, Identification of a family of muscarinic acetylcholine receptor genes, Science 237: 527 (1987).
T.I. Bonner, A.C. Young, M.R. Brann, and N.J. Buckley, Cloning and expression of the human and rat M5 muscarinic acetylcholine receptor genes, Neuron 1: 403 (1988).
C.F. Liao, A.P.N. Themmen, R. Joho, C. Barberis, M. Birnbaumer, and L. Birnbaumer, Molecular cloning and expression of a fifth muscarinic acetylcholine receptor, J. Biol. Chem. 264: 7328 (1989).
P. Davies and B.L. Woloszin, Recent advances in the neurochemistry of Alzheimer’s Disease, J. Clin. Psychiatry 48: 23 (1987).
M. McKinney and E. Richelson, The coupling of the neuronal muscarinic receptor to responses, Ann. Rev. Pharmacol. Toxicol. 24: 121 (1984).
A.G. Gilman, G proteins:transducers of receptor-generated signals. Ann. Rev. Biochem. 56: 615 (1987).
E.J. Neer and D.E. Clapham, Roles of G protein subunits in transmembrane signalling, Nature 333: 129 (1988).
K. Tanaka, M. Masu, and S. Nakanishi, Structure and functional expression of the cloned rat neurotensin receptor, Neuron 4: 847 (1990).
I. Gantz, M. Schaffer, J. Delvalle, C. Logsdon, V. Campbell, M. Uhler, and T. Yamada, Molecular cloning of a gene encoding the histamine H2 receptor, Proc. Natl. Acad. Sci. USA 88: 429 (1991).
H.-Y. Wang, L. Lipfer, C.C. Malbon, and S. Bahouth, Site directed anti-peptide antibodies define the topography of the β-adrenergic receptor, J. Biol. Chem. 264: 14424 (1989).
R.K. Goyal and S. Rattan, Neurohumoral, hormonal and drug receptors for the lower esophageal sphincter, Gastroenterology 74: 598 (1978).
V.W. Eberlein, G. Schmidt, A. Reuter, and E. Kutter, Anti-ulcer agent pirenzepine (L-S 519) — a tricyclic compound with particular physico-chemical properties, Arzneim-Forsch/Drug Res. 27: 356 (1977).
R. Hammer, C.P. Berrie, NJ.M. Birdsall, A.S.V. Burgen, and E.C. Hulme, Pirenzepine distinguishes between different subclasses of muscarinic receptors, Nature 283: 90 (1980).
M. Waelbroeck, M. Tastenoy, J. Camus, and J. Christophe, Binding of selective antagonists to four muscarinic receptors (Ml to M4) in rat forebrain, Mol. Pharmacol. 38: 267 (1990).
N. Birdsall, N. Buckley, H. Doods, K. Fukuda, A. Giachetti, R. Hammer, H. Kilbinger, G. Lambrecht, E. Mutschler, N. Nathanson, A. North, and R. Schwarz, Nomenclature for muscarinic receptor subtypes recommended by symposium, Trends Pharmacol. Sci. [Suppl] Dec.:Vii (1989).
F. Dorje, J. Wess, G. Lambrecht, R. Tacke, E. Mutschler, and M.R. Brann, Antagonist binding profiles of five cloned human muscarinic receptor subtypes, J. Pharmacol. Exp. Ther. 256: 727 (1990).
S.-C. Lin, K. Olson, H. Okazaki, and E. Richelson, Studies on muscarinic binding sites in human brain identified with [3H]pirenzepine, J. Neurochem. 46: 274 (1986).
S.J. Wall, R.P. Yasuda, F. Hory, S. Flagg, B.M. Martin, E.I. Ginns, and B.B. Wolfe, Production of antisera selective for M1-muscarinic receptors using fusion proteins — distribution of M1-receptors in rat brain, Mol. Pharmacol. 39: 643 (1991).
N.J. Buckley, T.I. Bonner, and M.R. Brann, Localization of a family of muscarinic receptor mRNAs in rat brain, J. Neurosci. 8: 4646 (1988).
M.T. Vilaro, J.M. Palacios, and G. Mengod, Localization of M5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry, Neurosci. Lett. 114: 154 (1990).
M.J. Blake, N.M. Appel, J.A. Joseph, C.A. Stagg, M. Anson, E.B. De Souza, and G.S. Roth, Muscarinic acetylcholine receptor subtype mRNA expression and ligand binding in the aged rat forebrain, Neurobiol. Aging 12: 193 (1991).
M.J. Berride, Receptors and calcium signalling, Trends Pharmacol. Sci. (November): 419 (1980).
S. Lazareno, D.A. Kendall, and S.R. Nahorski, Pirenzepine indicates heterogeneity of muscarinic receptors linked to cerebral inositol phospholipid metabolism, Neuropharmacology 24: 593 (1985).
C. Forray and E.E. El-Fakahany, On the involvement of multiple muscarinic receptor subtypes in the activation of phosphoinositide metabolism in rat cerebral cortex, Mol. Pharmacol. 37: 893 (1990).
M. Mckinney, D.J. Anderson, L. Vellarountree, T. Connolly, and J.H. Miller, Pharmacological profiles for rat cortical Ml and M2 muscarinic receptors using selective antagonists — comparison with N1E-115 muscarinic receptors, J. Pharmacol. Exp. Ther. 257: 1121 (1991).
A. Ashkenazi, J.W. Winslow, E.G. Peralta, G.L. Peterson, M.I. Schimerlik, D.J. Capon, and J. Ramachandran, An M2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover, Science 238: 672 (1987).
R. Stein, R. Pinkas-Kramarski, and M. Sokolovsky, Cloned Ml muscarinic receptors mediate both adenylate cyclase inhibition and phosphoinositide turnover. EMBO J. 7: 3031 (1988).
R.T. Bartus, R.L. Dean III, B. Beer, A.S. Lippa, The cholinergic hypothesis of geriatric memory dysfunction, Science 217: 408 (1982).
N. Sitaram, Cholinergic hypothesis of human memory:review of basic and clinical studies, Drug Develop. Res. 4: 481 (1984).
W.S.J. Messer, G.J. Thomas, W. Hoss, Selectivity of pirenzepine in the central nervous system. II. Differential effects of pirenzepine and scopolamine on performance of a representational memory task, Brain Res. 407: 37 (1987).
T.L. Yaksh, R. Dirksen, G.J. Harty, Antinociceptive effects of intrathecally injected cholinomimetic drugs in the rat and cat, Eur. J. Pharmacol. 117: 81 (1985).
R.L. Kohl, M.R. Lewis, Mechanisms underlying the antimotion sickness effects of psychostimulants, Aviat. Space Environ. Med. 58: 1215 (1987).
J. Velazquez-Moctezuma, J.C. Gillin, P.J. Shiromani, Effect of specific Ml, M2 muscarinic receptor agonists on REM sleep generation, Brain Research 503: 128 (1989).
V. Coiro, R. Volpi, P. Muzzetto, A. Caiazza, R. Petrolini, Cerri, R. Ruberti, and P. Chiodera, Cholinergic-muscarinic receptors participate in growth hormone secretion induced by lysine-8-vasopressin in man, Horm. Metabol. Res. 17: 316 (1985).
P. Carmeliet, C. Denef, Immunocytochemical and pharmacological evidence for an intrinsic cholinomimetic system modulating prolactin and growth hormone release in rat pituitary, Endocrinology 123: 1128 (1988).
D.S. Janowsky, M.K. El-Yousef, J.M. Davis, H.J. Sekerke, A cholinergic-adrenergic hypothesis of mania and depression, Lancet 1: 632 (1972).
J. Sitaram, J.I. Nurnberger Jr., E.S. Gershon, J.C. Gillin, Cholinergic regulation of mood and REM sleep:potential model and marker of vulnerability to effective disorder, Am. J. Psychiatry 139: 571 (1982).
DJ. Safer and R.P. Allen, The central effects of scopolamine in man, Biol. Psychiatry 3: 347 (1971).
D.A. Drachman and J. Leavitt, Human memory and the cholinergic system. A relationship to aging?, Arch. Neurol. 30: 113 (1974).
P. Davies and A.J.F. Maloney, Selective loss of central cholinergic neurons in Alzheimer’s disease, Lancet 11: 1403 (1976).
E.K. Perry, R.H. Perry, G. Blessed, and B.E. Tomlinson, Necropsy evidence of central cholinergic deficits in senile dementia, Lancet 1: 189 (1977).
H.C. Fibiger, Cholinergic mechanisms in learning, memory and dementia — a review of recent evidence, Trends Neurosci. 14: 220 (1991).
C. Bolden, B. Cusack, and E. Richelson, Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells, Eur. J. Pharmacol. 192: 205 (1991).
C.P. Bolden, B. Cusack, and E. Richelson, Clozapine is a potent and selective antagonist at the five cloned human muscarinic cholinergic receptors, FASEB J. 5: A487 (1991).
P. Davies and A.H. Verth, Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer’s-type dementia brains, Brain Res. 138: 385 (1978).
B.L. Holman, R.E. Gibson, T.C. Hill, W.C. Eckelman, M. Albert, and R.C. Reba, Muscarinic acetylcholine receptors in Alzheimer’s disease, JAMA 254: 3063 (1985).
D.C. Mash, D.D. Flynn, and L.T. Potter, Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer’s disease and experimental cholinergic denervation, Science 228: 1115 (1985).
J.O. Rinne, K. Laakso, P. Lonnberg, P. Molsa, L. Paljarvi, J.K. Rinne, E. Sako, and U.K. Rinne, Brain muscarinic receptors in senile dementia, Brain Res. 336: 19 (1985).
A. Nordberg, I. Alafuzoff, and B. Winblad, Muscarinic receptor subtypes in hippocampus in Alzheimer’s disease and mixed dementia type, Neurosci. Lett. 70: 160 (1986).
S. Shimohama, T. Taniguchi, M. Fujiwara, and M. Kameyama, Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia, J. Neurochem. 46: 288 (1986).
K.J. Reinikainen, P.J. Riekkinen, T. Halonen, and M. Laakso, Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer’s disease, Life Sci. 41: 453 (1987).
K.J. Kellar, P.J. Whitehouse, and A.M.E.A. Martino-Barrows, Muscarinic and nicotinic cholinergic binding sites in Alzheimer’s disease cerebral cortex, Brain Res. 436: 62 (1987).
E. Danielsson, S.-A. Eckernas, A. Westlind-Danielsson, O. Nordstrom, T. Bartfai, C.-G. Gottfries, and A. Wallin, VIP-sensitive adenylate cyclase, guanylate cyclase, muscarinic receptors, choline acetyltransferase and acetylcholinesterase, in brain tissue afflicted by Alzheimer’s disease/senile dementia of the Alzheimer type, Neurobiol. Aging 9: 153 (1988).
A. Probst, R. Cortes, J. Ulrich, and J.M. Palacios, Differential modification of muscarinic cholinergic receptors in the hippocampus of the patients with Alzheimer’s disease:an autoradiographic study. Brain Res. 450: 190 (1988).
K.W. Lange, F.R. Wells, M.N. Rossor, P. Jenner, and C.D. Marsden, Brain muscarinic receptors in Alzheimer’s and Parkinson’s diseases, Lancet November 25: 1279 (1989).
J.O. Rinne, P. Lonnberg, P. Marjamaki, and U.K. Rinne, Brain muscarinic receptor subtypes are differently affected in Alzheimer’s disease and Parkinson’s disease, Brain Res. 483: 402 (1989).
R. Quirion, I. Aubert, P.A. Lapchak, R.P. Schaum, S. Teolis, S. Gauthier, and D.M. Araujo, Muscarinic receptor subtypes in human neurodegenerative disorder:focus on Alzheimer’s disease, Subtypes of Muscarinic Receptors, Trends, Pharmacol. Sci. IV, Suppl.: 80 (1990).
J.B. Penney, W.F. Maragos, J.T. Greenamyre, D.L. Debowey, Z. Hollingsworth, and A.B. Young, Excitatory amino acids binding sites in the hippocampal region of Alzheimer’s disease and other dementias, J. Neurol., Neurosurg., Psychiat. 53: 314 (1990).
E.K. Perry, C.J. Smith, J.A. Court, and R.H. Perry, Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types, J. Neural Transm. [P-D Sect] 2: 149 (1990).
T. Sakurada, I. Alufuzoff, B. Winblad, and A. Nordberg, Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer’s disease and multi-infarct dementia, Brain Research 521: 329 (1990).
B.A. Vogt, P.B. Crino, and L. Volicer, Laminar alterations in γ-aminobutyric acidA, muscarinic, and β-adrenoceptors and neuron degeneration in cingulate cortex in Alzheimer’s disease, J. Neurochem. 57: 282 (1991).
S. Shimohama, T. Taniguchi, M. Fujiwara, and M. Kameyama, Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia, J. Neurochem. 46: 288 (1986).
K.J. Kellar, P.J. Whitehouse, A.M. Martino-Barrows, K. Marcus, and D.L. Price, Muscarinic and nicotinic cholinergic binding sites in Alzheimer’s disease cerebral cortex, Brain Res. 436: 62 (1987).
P.J. Whitehouse, A.M. Maitino, K.A. Marcus, R.M. Zweig, H.S. Singer, D.L. Price, and K.J. Kellar, Reductions in acetylcholine and nicotine binding in several degenerative disease, Arch. Neurol. 45: 722 (1988).
D.M. Araujo, P.A. Lapchak, Y. Robitaille, S. Gauthier, and R. Quirion, Differential alteration of various cholinergic markers in cortical subcortical regions of human brain in Alzheimer’s disease, J. Neurochem. 50: 1914 (1988).
E.D. London, M.J. Ball, and S.B. Waller, Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer’s dementia, Neurochem. Res. 14: 745 (1989).
K. Sugaya, E. Giacobini, and V.A. Chiappinelli, Nicotinic acetylcholine receptor subtypes in human frontal cortex:changes in Alzheimer’s disease, J. Neurosci. Res. 27: 349 (1990).
H. Schroder, E. Giacobini, R.G. Struble, K. Zilles, and A. Maelicke, Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer’s disease, Neurobiol. Aging 12: 259 (1991).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Richelson, E. (1992). Muscarinic Receptors: Molecular Biology and Neuropsychopharmacology. In: Meyer, E.M., Simpkins, J.W., Yamamoto, J., Crews, F.T. (eds) Treatment of Dementias. Advances in Behavioral Biology, vol 40. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3432-7_1
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3432-7_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6518-1
Online ISBN: 978-1-4615-3432-7
eBook Packages: Springer Book Archive